Management of hypertension among patients with coronary heart disease

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Olafiranye, Oladipupo ^a,b   Zizi, Ferdinand ^a   Brimah, Perry ^a   Jean Louis, Girardin ^a   Makaryus, Amgad N ^c   McFarlane, Samy ^b   Ogedegbe, Gbenga ^d  

^a Downstate Health Sciences University   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; METOPROLOL; NIFEDIPINE; NITRATE; PERINDOPRIL; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; AORTA DISEASE; ARTERIAL STIFFNESS; ARTICLE; ATHEROGENESIS; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG CONTRAINDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART AFTERLOAD; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SMOKING CESSATION; SODIUM RESTRICTION; STRESS MANAGEMENT;

EID: 80055039456     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/653903     Document Type: Article

References (62)

1. Chobanian A. V., Bakris G. L., Black H. R., Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 1206 1252 (Pubitemid 37553153)
2. Burt V. L., Whelton P., Roccella E. J., Brown C., Cutler J. A., Higgins M., Horan M. J., Labarthe D., Prevalence of hypertension in the US adult population: results from the 3rd National Health and Nutrition Examination Survey, 19881991. Hypertension 1995 25 3 305 313 2-s2.0-0028942436
3. Yusuf P. S., yusufs@mcmaster.ca Hawken S., Ôunpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 2004 364 9438 937 952 10.1016/S0140-6736(04)17018-9 (Pubitemid 39208455)
4. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 2002 360 9349 1903 1913 2-s2.0-0037079309 10.1016/S0140-6736(02)11911-8 (Pubitemid 35472129)
5. Whelton P. K., He J., Muntner P., Prevelance, awareness, treatment and control of hypertension in North America, North Africa and Asia. Journal of Human Hypertension 2004 18 8 545 551 2-s2.0-4444252859 10.1038/sj.jhh.1001701 (Pubitemid 39173530)
6. American Heart Association, Heart Disease and Stroke Statistics-2007 Update 2007 Dallas, Tex, USA American Heart Association
7. Murray C. J., Lopez A. D., The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020 1996 1 Cambridge, Mass, USA Harvard School of Public Health Global Burden of Disease and Injury Series
8. Ôunpuu S., Negassa A., Yusuf S., INTER-HEART: a global study of risk factors for acute myocardial infarction. American Heart Journal 2001 141 5 711 721 2-s2.0-0035028919 10.1067/mhj.2001.114974 (Pubitemid 32378478)
9. Okrainec K., Banerjee D. K., Eisenberg M. J., Coronary artery disease in the developing world. American Heart Journal 2004 148 1 7 15 2-s2.0-3142579188 10.1016/j.ahj.2003.11.027 (Pubitemid 38900475)
10. Rosendorff C., Black H. R., Cannon C. P., Gersh B. J., Gore J., Izzo J. L., Kaplan N. M., O'Connor C. M., O'Gara P. T., Oparil S., Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 2007 115 21 2761 2788 2-s2.0-34249655660 10.1161/CIRCULATIONAHA.107.183885 (Pubitemid 46842793)
11. Oparil S., Zaman M. A., Calhoun D. A., Pathogenesis of hypertension. Annals of Internal Medicine 2003 139 9 761 776 2-s2.0-0642341369 (Pubitemid 38139234)
12. Dzau V., The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. Journal of Hypertension 2005 23 1, supplement S9 S17 2-s2.0-18544369738
13. Levy D., Anderson K. M., Savage D. D., Kannel W. B., Christiansen J. C., Castelli W. P., Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham heart study. Annals of Internal Medicine 1988 108 1 7 13 2-s2.0-0023879355 (Pubitemid 18081162)
14. Rheeder P., Stolk R. P., Mosterd A., Pols H. A. P., Hofman A., Grobbee D. E., Insulin resistance syndrome and left ventricular mass in an elderly population (the Rotterdam study). American Journal of Cardiology 1999 84 2 233 236 2-s2.0-0032814636 10.1016/S0002-9149(99)00243-X (Pubitemid 29331348)
15. Frohlich E. D., Hypertension, left ventricular hypertrophy, and coronary flow reserve. Advances in Experimental Medicine and Biology 1997 432 253 262 2-s2.0-0031440556 (Pubitemid 28036017)
16. Kannel W. B., Wilson P. W. F., Izzo J. L. Jr., Black H. R., Cardiovascular risk factors and hypertension. Hypertension Primer 2003 3rd Dallas, Tex, USA American Heart Association 235 238
17. Vaitkevicius P. V., Fleg J. L., Engel J. H., O'Connor F. C., Wright J. G., Lakatta L. E., Yin F. C. P., Lakatta E. G., Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993 88 4 1456 1462 2-s2.0-0027429164 (Pubitemid 23296891)
18. McGuire K. A., Janssen I., Ross R., Ability of physical activity to predict cardiovascular disease beyond commonly evaluated cardiometabolic risk factors. American Journal of Cardiology 2009 104 11 1522 1526 2-s2.0-71649113471 10.1016/j.amjcard.2009.07.023
19. Hambrecht R., Wolf A., Gielen S., Linke A., Hofer J., Erbs S., Schoene N., Schuler G., Effect of exercise on coronary endothelial function in patients with coronary artery disease. New England Journal of Medicine 2000 342 7 454 460 2-s2.0-0034677448 10.1056/NEJM200002173420702 (Pubitemid 30100232)
20. Bauman A. E., Updating the evidence that physical activity is good for health: an epidemiological review 20002003. Journal of Science and Medicine in Sport 2004 7 1 6 19 2-s2.0-3242765427
21. Rozanski A., Blumenthal J. A., Kaplan J., Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999 99 16 2192 2217 2-s2.0-0033608949 (Pubitemid 29196806)
22. Antman E. M., Anbe D. T., Armstrong P. W., ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004 110 588 636 (Pubitemid 39036178)
23. Antman E. M., Anbe D. T., Armstrong P. W., ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2005 111 2013
24. Gibbons R. J., Abrams J., Chatterjee K., Daley J., Deedwania P. C., Douglas J. S., Ferguson T. B., Fihn S. D., Fraker T. D., Gardin J. M., O'Rourke R. A., Pasternak R. C., Williams S. V., Alpert J. S., Antman E. M., Hiratzka L. F., Fuster V., Faxon D. P., Gregoratos G., Jacobs A. K., Smith S. C., ACC/AHA 2002 guideline update for the management of patients with chronic stable anginasummary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Journal of the American College of Cardiology 2003 41 1 159 168 2-s2.0-0037221387 10.1016/S0735-1097(02)02848-6 (Pubitemid 36044419)
25. Wang J. G., Staessen J. A., Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. Journal of Clinical Hypertension 2003 5 1 66 75 2-s2.0-0037277966 (Pubitemid 36221564)
26. Viskin S., Kitzis I., Lev E., Zak Z., Heller K., Villa Y., Zajarias A., Laniado S., Belhassen B., Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. Journal of the American College of Cardiology 1995 25 6 1327 1332 2-s2.0-0028965782 10.1016/0735-1097(94)00552-2
27. Goldstein S., β -Blockers in hypertensive and coronary heart disease. Archives of Internal Medicine 1996 156 12 1267 1276 2-s2.0-0030007638 10.1001/archinte.156.12.1267 (Pubitemid 26197698)
28. Frishman W. H., Cheng A., Secondary prevention of myocardial infarction: role of β adrenegic blockers and angiostein converting enzyme inhibitors. American Heart Journal 1999 137 S25 S34 (Pubitemid 29162889)
29. Dahlöf B., bjorn.dahlof@scri.se Sever P. S., Poulter N. R., Wedel H., Beevers D. G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Östergren J., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 2005 366 9489 895 906 10.1016/S0140-6736(05)67185-1 (Pubitemid 41265663)
30. Williams B., bw17@le.ac.uk Lacy P. S., psl2@le.ac.uk Thom S. M., Cruickshank K., Stanton A., Collier D., Hughes A. D., Thurston H., O'Rourke M., Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006 113 9 1213 1225 10.1161/CIRCULATIONAHA.105.595496
31. Olafiranye O., Qureshi G., Salciccioli L., Weber M., Lazar J. M., Association of beta-blocker use with increased aortic wave reflection. Journal of the American Society of Hypertension 2008 2 2 64 69 2-s2.0-40649090892 10.1016/j.jash.2007.10.007 (Pubitemid 351372847)
32. Rosendorff C., Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opinion on Pharmacotherapy 2003 4 9 1535 1541 2-s2.0-0141851858 10.1517/14656566.4.9.1535 (Pubitemid 37120900)
33. Black H. R., hblack@rush.edu Elliott W. J., Grandits G., Grambsch P., Lucente T., White W. B., Neaton J. D., Grimm Jr. R. H., Hansson L., Lacourcière Y., Muller J., Sleight P., Weber M. A., Williams G., Wittes J., Zanchetti A., Anders R. J., Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. Journal of the American Medical Association 2003 289 16 2073 2082 10.1001/jama.289.16. 2073 (Pubitemid 37430209)
34. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S. E., Lindholm L. H., Syvertsen J. O., Lanke J., De Faire U., Dahlöf B., Karlberg B. E., Randomised trial of effects of calcium antagonists compared with diuretics and β -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. The Lancet 2000 356 9227 359 365 2-s2.0-0034730027 (Pubitemid 30487491)
35. Pepine C. J., Handberg E. M., Cooper-DeHoff R. M., Marks R. G., Kowey P., Messerli F. H., Mancia G., Cangiano J. L., Garcia-Barreto D., Keltai M., Erdine S., Bristol H. A., Kolb H. R., Bakris G. L., Cohen J. D., Parmley W. W., A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the international verapamil- trandolapril study (INVEST): a randomized controlled trial. Journal of the American Medical Association 2003 290 21 2805 2816 2-s2.0-0345492460 10.1001/jama.290.21.2805 (Pubitemid 37509488)
36. Goldstein R. E., Boccuzzi S. J., Cruess D., Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991 83 52 60
37. ALLHAT-Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 2002 288 2981 2997
38. ALLHAT-Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 2003 289 178
39. ALLHAT-Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 2004 291 2196
40. Julius S., Kjeldsen S. E., Weber M., Brunner H. R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G. T., Mitchell L., Plat F., Schork A., Smith B., Zanchetti A., Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 2004 363 9426 2022 2031 2-s2.0-2942635317 10.1016/S0140- 6736(04)16451-9 (Pubitemid 38781102)
41. Hunt S. A., Abraham W. T., Chin M. H., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 112 e154 e235
42. Alderman M. H., Cohen H., Roqué R., Madhavan S., Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. The Lancet 1997 349 9052 594 598 2-s2.0-0031053865 10.1016/S0140-6736(96)08359-6 (Pubitemid 27101885)
43. Hennekens C. H., Albert C. M., Godfried S. L., Gaziano J. M., Buring J. E., Drug therapy: adjunctive drug therapy of acute myocardial infarctionevidence from clinical trials. New England Journal of Medicine 1996 335 22 1660 1667 2-s2.0-0030605215 10.1056/NEJM199611283352207 (Pubitemid 26392732)
44. Turnbull F., fturnbull@iih.usyd.edu.au Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet 2003 362 9395 1527 1535 10.1016/S0140-6736(03)14739-3 (Pubitemid 37410190)
45. Mason R. P., Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002 165 2 191 199 2-s2.0-0036889629 10.1016/S0021-9150(01)00729-8 (Pubitemid 35333345)
46. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group, ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. The Lancet 1995 345 669 685
47. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, GISSI-3: effects of lisinopri1 and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. The Lancet 1994 343 1115 1122
48. Fox K. M., EURopean Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet 2003 362 782 788 (Pubitemid 37093919)
49. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation study. New England Journal of Medicine 2000 342 145 153 (Pubitemid 30051645)
50. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation study. New England Journal of Medicine 2000 342 1376
51. Svensson P., de Faire U., Sleight P., Yusuf S., Ostergren J., Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001 38 6 E28 E32 2-s2.0-17044440752
52. Braunwald E., Domanski M. J., Fowler S. E., Geller N. L., Gersh B. J., Hsia J., Pfeffer M. A., Rice M. M., Rosenberg Y. D., Rouleau J. L., Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine 2004 351 20 2058 2068 10.1056/NEJMoa042739 (Pubitemid 39482499)
53. ACE Inhibitor Myocardial Infarction Collaborative Group, Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998 97 22 2202 2212 2-s2.0-0032499670
54. Flather M. D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., Torp-Pedersen C., Ball S., Pogue J., Moyé L., Braunwald E., Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet 2000 355 9215 1575 1581 2-s2.0-0010838455 (Pubitemid 30240501)
55. Pfeffer M. A., mpfeffer@rics.bwh.harvard.edu McMurray J. J. V., Velazquez E. J., Rouleau J.-L., Kober L., Maggioni A. P., Solomon S. D., Swedberg K., Van de Werf F., White H., Leimberger J. D., Henis M., Edwards S., Zelenkofske S., Sellers M. A., Califf R. M., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2003 349 20 1893 1906 10.1056/NEJMoa032292 (Pubitemid 37409706)
56. Pfeffer M. A., mpfeffer@rics.bwh.harvard.edu McMurray J. J. V., Velazquez E. J., Rouleau J.-L., Kober L., Maggioni A. P., Solomon S. D., Swedberg K., Van de Werf F., White H., Leimberger J. D., Henis M., Edwards S., Zelenkofske S., Sellers M. A., Califf R. M., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2004 350 203
57. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., Norgiolini S., Bracco C., Porcellati C., Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004 43 5 963 969 2-s2.0-2342652390 10.1161/01.HYP.0000125726.92964.ab (Pubitemid 38579899)
58. SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). Journal of the American Medical Association 1991 265 24 3255 3264 10.1001/jama.265.24.3255
59. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. Journal of the American Medical Association 1970 213 1143 1152
60. Medical Research Council Working Party, MRC trial of treatment of mild hypertension: principal results. British Medical Journal 1985 291 6488 97 104
61. Wang J. G., Staessen J. A., Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. Journal of Clinical Hypertension 2003 5 1 66 75 2-s2.0-0037277966 (Pubitemid 36221564)
62. Staessen J. A., Wang J.-G., Thijs L., Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. Journal of Hypertension 2003 21 6 1055 1076 2-s2.0-0038203004 10.1097/00004872- 200306000-00002 (Pubitemid 36667856)